Fresenius Kabi Braced For ‘Pyrrhic Victory’ In Akorn Damages Lawsuit
As COVID-19 Takes A Bite Out Of Profit
Fresenius Kabi says a decision on damages stemming from its aborted takeover of troubled Akorn is expected imminently, but has underlined it will not reap enormous riches with a victory. Meanwhile, the German firm has just initiated Phase III trials for a key biosimilar candidate.
